Effects of emicizumab on APTT, one‐stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors-Reference-Cited by-同舟云学术

Effects of emicizumab on APTT, one‐stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors

Published:2020-04-06 Issue:3 Volume:26 Page:536-542
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Bowyer Annette¹^ORCID,Kitchen Steve¹^ORCID,Maclean Rhona¹

Affiliation:

1. Department of Coagulation Sheffield Haemophilia and Thrombosis Centre Royal Hallamshire Hospital Sheffield UK

Funder

Roche

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.13990

Reference15 articles.

1. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model

2. Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia A

3. Emicizumab Prophylaxis in Hemophilia A with Inhibitors

4. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

5. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multicenter evaluation of the hemostatic activity of emicizumab in patients with severe hemophilia A;Journal of Thrombosis and Haemostasis;2024-07

2. Evaluating Factor VIII Concentrates Using Clot Waveform Analysis;Journal of Clinical Medicine;2024-06-30

3. Strategies for Performing Factor Assays in the Presence of Emicizumab or Other Novel/Emerging Hemostatic Agents;Seminars in Thrombosis and Hemostasis;2024-06-12

4. Clot formation and fibrinolysis assays reveal functional differences among hemostatic agents in hemophilia A plasma;Research and Practice in Thrombosis and Haemostasis;2024-01

5. Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks;Research and Practice in Thrombosis and Haemostasis;2024-01